Last reviewed · How we verify
VVZ-149 Injections
VVZ-149 Injections is a PD-1 inhibitor Small molecule drug developed by Vivozon, Inc.. It is currently in Phase 3 development for Non-small cell lung cancer, PD-L1 positive. Also known as: Opiranserin Injections, VVZ-149 injection or water for injection, Colorless, transparent liquid in water for injection, VVZ-149 injection.
VVZ-149 Injections is a monoclonal antibody that targets the PD-1 receptor.
VVZ-149 Injections is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | VVZ-149 Injections |
|---|---|
| Also known as | Opiranserin Injections, VVZ-149 injection or water for injection, Colorless, transparent liquid in water for injection, VVZ-149 injection |
| Sponsor | Vivozon, Inc. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, VVZ-149 Injections prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
- Efficacy and Safety of VVZ-149 Injections in Patients Undergoing Laparoscopic Colectomy (PHASE3)
- Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-Operative Pain Following Abdominoplasty (PHASE3)
- Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Laparoscopic Colorectomy (PHASE2)
- Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Colorectal Surgery (PHASE2)
- Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Postoperative Pain Following Bunionectomy (PHASE2)
- Phase 3 Efficacy and Safety Study of VVZ-149 Injections for Postoperative Pain Following Bunionectomy (PHASE3)
- Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects (PHASE1)
- Phase I Study to Investigate Safety, Tolerability, and Pharmacokinetics of VVZ-149 Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VVZ-149 Injections CI brief — competitive landscape report
- VVZ-149 Injections updates RSS · CI watch RSS
- Vivozon, Inc. portfolio CI
Frequently asked questions about VVZ-149 Injections
What is VVZ-149 Injections?
How does VVZ-149 Injections work?
What is VVZ-149 Injections used for?
Who makes VVZ-149 Injections?
Is VVZ-149 Injections also known as anything else?
What drug class is VVZ-149 Injections in?
What development phase is VVZ-149 Injections in?
What are the side effects of VVZ-149 Injections?
What does VVZ-149 Injections target?
Related
- Drug class: All PD-1 inhibitor drugs
- Target: All drugs targeting PD-1
- Manufacturer: Vivozon, Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer, PD-L1 positive
- Also known as: Opiranserin Injections, VVZ-149 injection or water for injection, Colorless, transparent liquid in water for injection, VVZ-149 injection
- Compare: VVZ-149 Injections vs similar drugs
- Pricing: VVZ-149 Injections cost, discount & access